In addition to CVD [1], higher levels of this inflammation biomarker are also reported in states with diminished insulin sensitivity, such as type 2 diabetes [5], [6], polycystic ovary syndrome [7], nonalcoholic fatty liver disease (NAFLD) [8], which raises the question whether endocan might represent the link between inflammation in all these mentioned disorders and CVD. Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.